1. 1. Sato H, Sasaki N, Harada S, Tanaka T, Akasu F, Asayama K, et al. Guidelines for the treatment of childhood-onset Graves’ disease with antithyroid drug in Japan, 2008. J Jpn Pediatr Soc 2008;112: 946-52.
2. 2. Rivkees SA, Mattison DR. Propylthiouracil (PTU) hepatoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol 2009;2009:132041. doi: 10.1155/2009/132041.
3. 3. Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab 2010;95: 3260-7.
4. 4. Reinwein D, Benker G, Lazarus JH, Alexander WD. A prospective randomized trial of antithyroid drug dose in Graves’ disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment. J Clin Endocrinol Metab 1993;76: 1516-21.
5. 5. Rivkees SA, Stepenson K, Dinauer K. Adverse events associated with methimazole therapy of Graves’ disease in children. Int J Pediatr Endocrinol 2009;2009:176970. doi: 10.1155/2009/176970.